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ABSTRACTS 
Objective: A recent clinical study demonstrated that sodium benzoate (SB), a prototype 
competitive D-amino acid oxidase (DAAO) inhibitor, was effective in the treatment of 
several symptoms such as positive and negative symptoms, and cognitive impairment, 
in medicated patients with schizophrenia. The objective of the study was undertaken to 
examine the effects of SB on behavioral abnormalities, such as prepulse inhibition (PPI) 
deficits and hyperlocomotion in mice, after a single administration of the 
N-methyl-D-aspartate (NMDA) receptor antagonist, phencyclidine (PCP). 
Methods: Effects of SB on behavioral abnormalities (PPI deficits and hyperlocomotion) 
in mice after PCP administration were examined. Furthermore, effects of SB on tissue 
levels of amino acids were also examined. 
Results: A single oral dose of SB (100, 300 or 1000 mg/kg) attenuated PPI deficits in 
mice after administration of PCP (3.0 mg/kg, s.c.), in a dose dependent manner. In 
contrast, L-701,324 (10 mg/kg), an antagonist at glycine-site of the NMDA receptor, did 
not affect the effect of SB (1000 mg/kg) on PCP-induced PPI deficits. Furthermore, a 
single oral dose of SB (1000 mg/kg) significantly attenuated the hyperlocomotion in 
mice after administration of PCP (3.0 mg/kg, s.c.). However, a single oral dose of SB 
(1000 mg/kg) caused no changes to D-serine levels in plasma or the frontal cortex, 
hippocampus and striatum of these animals.  
Conclusion: This study suggests that SB induced antipsychotic effects in the PCP 
model of schizophrenia, even though it did not increase D-serine levels in the brain.  
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Significance outcomes 
 Pretreatment with sodium benzoate (SB), a prototype D-amino acid oxidase 
(DAAO) inhibitor, attenuated prepulse inhibition deficits and hyperlocomotion in 
mice after a single administration of phencyclidine. 
 However, a single administration of SB did not affect D-serine levels in the blood 
and brain. 
 
Limitations of the study 
 In this study, we did not measure D-serine levels in the cerebellum where DAAO is 
rich. 
 The effects of SB in other models of schizophrenia should be examined. 
 The effects of chronic administration of SB on levels of amino acids in the brain 
should be examined. 
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Introduction 
Multiple lines of evidence suggest that dysfunctional glutamatergic neurotransmission 
via N-methyl-D-aspartate (NMDA) receptors are involved in the pathophysiology of 
schizophrenia [1-9]. The NMDA receptor antagonists, phencyclidine (PCP), and 
ketamine induce schizophrenia-like symptoms, including positive and negative 
symptoms, and cognitive impairment in healthy subjects [1, 10-12]. This resulted in the 
frequent use of PCP to generate animal models of schizophrenia [13-22].  
Accumulating evidence suggests that disturbed NMDA receptor 
neurotransmission, due to decreased D-serine levels, may be a causative factor in the 
pathophysiology of schizophrenia [6, 7, 23-25]. These findings include firstly, lower 
levels of D-serine in the blood, cerebrospinal fluid (CSF), and postmortem brain tissue 
from patients with schizophrenia, relative to normal controls [26-30]. Secondly, 
treatment with D-serine reduces positive, negative and cognitive symptoms in patients 
with schizophrenia [31-35]. In addition, a recent meta-analysis supports the findings 
that D-serine is effective in the treatment of schizophrenia [36]. Thirdly, mRNA 
expression and the activity of D-amino acid oxidase (DAAO), the enzyme which 
metabolizes D-serine, is increased in postmortem brains from patients with 
schizophrenia [37, 38]. Fourthly, the G72 gene, located at chromosome 13q, shows 
significant association with schizophrenia [39, 40]. This gene has been designated a 
DAAO activator, since the G72 protein interacts physically with DAAO [39]. 
Subsequent meta-analysis found highly significant association between nucleotide 
variations in the G72/G30 region and schizophrenia [41].  
Klein and Kamin [42] first reported on SB as a prototype competitive DAAO 
inhibitor (Ki ≈ 16 μM), as early as the 1940s [43]. More recently, Lane et al. [44] 
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performed a randomized, double-blind, placebo-controlled study using SB in stabilized 
patients with schizophrenia. Given at a dose of 1 g/day for 6 weeks, SB produced a 21% 
improvement in Positive and Negative Syndrome Scale (PANSS) total scores and large 
effect sizes in the PANSS total and subscales, Scales for the Assessment of Negative 
Symptoms (SANSS) - 20 items, Global Assessment of Function (GAF), Quality of Life 
(QOL) Scale, and Clinical Global Impression (CGI), as well as improved 
neurocognition [44]. Additionally, SB was well tolerated without significant adverse 
effects. However, there are no reports demonstrating the antipsychotic effects of SB in 
animal models of schizophrenia, even though SB could be a potential therapeutic drug 
for this disorder. 
In the present study, we examined whether SB attenuated prepulse inhibition 
(PPI) deficits and hyperlocomotion in mice, after the administration of PCP. In addition, 
we measured levels of D-serine in blood and brain regions after oral administration of 
SB. We also measured levels of other the amino acids, L-serine, glycine, glutamate, 
glutamine and γ-aminobutyric acid (GABA), since they are involved in the glutamine – 
glutamate – GABA cycle [9, 45, 46]. 
Materials and methods 
Animals 
Male ddY mice (8 weeks old) weighing 25 – 30 g were purchased from SLC Japan 
(Hamamatsu, Shizuoka, Japan). The mice were housed in clear polycarbonate cages 
(22.5×33.8×14.0 cm) in groups of 5 or 6 per cage under a controlled 12/12-h light–dark 
cycle (lights on from 7:00 AM to 7:00 PM), with room temperature at 23 ± 1°C and 
humidity at 55 ± 5%. The mice were given free access to water and food pellets. The 
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experimental procedure was approved by the Animal Care and Use Committee of Chiba 
University.  
Drugs 
Sodium benzoate (SB; Wako Pure Chemical Co., Tokyo, Japan) was dissolved in 0.5% 
carboxymethy cellulose (CMC) (Wako Pure Chemical Co., Tokyo, Japan). PCP 
hydrochloride was synthesized in our laboratory, and the dose (3.0 mg/kg) of PCP was 
expressed as a hydrochloride salt [22]. L-701,324 (Sigma-Aldrich Co., Ltd., St Louis, 
MO, USA) was dissolved in 20% polyethylene glycol (PEG300: Wako Pure Chemical 
Co., Tokyo, Japan) with pH adjusted to 10 with 1M NaOH. Other drugs were purchased 
from commercial sources.  
Effect of SB on PPI deficits after a single administration of PCP  
The mice were tested for their acoustic startle reactivity (ASR) in a startle chamber 
(SR-LAB; San Diego Instruments, San Diego, CA, USA) using the standard methods 
described previously [22, 47-50]. The test sessions were begun after an initial 10-min 
acclimation period in the chamber. The mice were subjected to one of six trials: (1) 
pulse alone, as a 40 ms broadband burst; a pulse (40 ms broadband burst) preceded by 
100 ms with a 20 ms prepulse that was (2) 4 dB, (3) 8 dB, (4) 12 dB, or (5) 16 dB over 
background (65 dB); and (6) background only (no stimulus). The amount of prepulse 
inhibition (PPI) was expressed as the percentage decrease in the amplitude of the startle 
reactivity caused by presentation of the prepulse (% PPI). SB (30, 100 or 1000 mg/kg), 
or vehicle (0.5 % CMC) (10 ml/kg) was administered orally 60 min (including the 
10-min acclimation period) before the machine records, and PCP (3.0 mg/kg) or saline 
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(10 ml/kg) was administered subcutaneously (s.c.) 10 min (including the 10-min 
acclimation period) before. The PPI test lasted 20 min in total.  
Effect of SB and L-701,324 on PPI deficits after a single administration of PCP  
In order to study the role of glycine-site of the NMDA receptor, we examined the effects 
of L-701,324, an antagonist of glycine-site of the NMDA receptor, on the effect of SB 
on PCP-induced PPI deficits in mice. Thirty minutes after oral administration of SB 
(1000 mg/kg), or vehicle (0.5 % CMC) (10 ml/kg), L-701,324 (10 mg/kg) or vehicle 
(20% PEG) was administered intraperitoneally (i.p.) 30 minute later. Thirty minute after 
injection of L-701,324 (or vehicle), PCP (3.0 mg/kg) or saline (10 ml/kg) was 
administered s.c.. The PPI test was performed as described above. 
Effect of SB on hyperlocomotion after a single administration of PCP  
After habituation (30 min) in the cage, SB or vehicle was injected into mice (each group 
n = 8 – 12). One hour after a single oral administration of SB (1000 mg/kg) or vehicle 
(10 ml/kg, 0.5% CMC), PCP (3.0 mg/kg) or vehicle (physiological saline; 10 ml/kg) 
was administered s.c. into the mice. Locomotor activity was measured using an animal 
movement analysis system (SCANET MV-40, Melquest, Toyama, Japan). The system 
consisted of a rectangular enclosure (560 x 560 mm). The side walls (height, 60 mm) of 
the enclosure were equipped with 144 pairs of photosensors located at 6-mm intervals at 
a height of 30 mm from the bottom edge. An animal was placed in the observation cage 
30 minutes (habituation) before injection of vehicle or SB. Vehicle or PCP was injected 
60 minutes after oral injection of vehicle or SB, and the locomotion activity was 
measured for 60 minutes after injection of vehicle or PCP. A pair of photosensors was 
 8 
scanned every 0.1 second to detect the animal’s movements. The intersection of paired 
photosensors (10 mm apart) in the enclosure was counted as one unit of locomotor 
activity. Data collected for total 150 minutes were used in this study. The sum of 
locomotion in mice for 60 minutes after the PCP administration was used for data 
analysis. 
Measurement of amino acids by high performance liquid chromatography (HPLC) 
One hour after a single oral administration of SB (1000 mg/kg), mice were sacrificed by 
decapitation after collection of blood sample. The brain was removed and the frontal 
cortex, hippocampus, and striatum were dissected on ice. Plasma and brain tissues were 
frozen on dry ice and stored at -80 °C until measurement. 
Briefly, plasma (20 µL) was homogenized in 180 µL of methanol (HPLC grade) 
on ice. The homogenates were centrifuged at 3,000 x g for 6 min at 4°C, and 20 µL of 
supernatant was evaporated to dryness at 40°C. To the residue, 20 µl of H2O (HPLC 
grade), 20 μL of 0.1 M borate buffer (pH 8.0) and 60 μL of 50 mM 
4-fluoro-7-nitro-2,1,3-benzoxadiazole (NBD-F; Tokyo Kasei Kogyo Co., Ltd., Tokyo, 
Japan) in CH3CN (HPLC grade) were added. The reaction mixture was then heated at 
60°C for 2 min, and immediately supplemented with 100 μL of H2O/CH3CN (90/10) 
containing 0.1 % trifluoroacetic acid to stop the reaction. Brain tissues were 
homogenized in 1.5 mL of methanol (HPLC grade) on ice. The homogenates were 
centrifuged at 3000g for 6 min at 4 °C, and 20 μL of supernatant was evaporated to 
dryness at 40 °C. To the residue, 20 μL of H2O (HPLC grade), 20 μL of 0.1 M borate 
buffer (pH 8.0), and 60 μL of 50 mM NBD-F in CH3CN (HPLC grade) were added. The 
reaction mixture was then heated to 60 °C for 2 min, and immediately supplemented 
with 100 μL of H2O/acetonitrile (90/10) containing 0.1% trifluoroacetic acid (TFA) to 
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stop the reaction. Levels of amino acids (D-serine, L-serine, glycine, glutamine, 
glutamate, GABA) were measured using high performance liquid chromatography 
(HPLC) system (Shimadzu Corporation, Kyoto, Japan), as previously reported [51-53]. 
Fluorescence detection was performed at 530 nm with an excitation wavelength of 470 
nm.  
Statistical Analysis 
The data are presented as the mean ± standard error of the mean (S.E.M.). The PPI data 
were analyzed by multivariate analysis of variance (MANOVA), followed by post-hoc 
Fisher’s Least Significance Difference (LSD) test. The data of hyperlocomotion were 
analyzed by one-way analysis of variance (ANOVA), followed by post-hoc Fisher LSD 
test. The data of amino acids were analyzed using Student t-test. Significance for the 
results was set at P < 0.05. 
Results 
Figure 1 shows the effects of SB (100, 300 or 1000 mg/kg) on PCP (3.0 mg/kg)-induced 
PPI deficits in mice. The MANOVA analysis of all PPI data revealed that there was a 
significant effect [Wilks lambda = 0.346, P < 0.001]. Subsequent ANOVA analysis 
revealed the significant differences (P < 0.001) at all dB groups (69, 73, 77, and 81 dB). 
A post-hoc analysis indicated a significant (P < 0.001) difference in PPI deficits 
between the vehicle + vehicle group and vehicle + PCP (3.0 mg/kg) group at all dB 
groups (Figure 1). Pretreatment with SB (100, 300 or 1000 mg/kg) attenuated 
PCP-induced PPI deficits, in a dose dependent manner. High dose (1000 mg/kg) of SB 
significantly (P < 0.001) attenuated PCP-induced PPI deficits at all dB groups (Figure 1). 
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Moderate dose (300 mg/kg) of SB significantly (P < 0.05 at 69 – 77 dB groups, P < 
0.001 at 81 dB group) attenuated PCP-induced PPI deficits at all dB groups (Figure 1). 
In contrast, PPI in mice after administration of SB (1000 mg/kg) alone was similar to 
control mice (Figure 1). 
In order to study the role of glycine-site of the NMDA receptor, we examined the 
effect of L-701,324, an antagonist at glycine-site of the NMDA receptor, on effect of SB 
on PCP-induced PPI deficits. Figure 2 shows the effects of SB (1000 mg/kg) and L-701, 
324 (10 mg/kg) on PCP (3.0 mg/kg)-induced PPI deficits in mice. The MANOVA 
analysis of all PPI data revealed that there was a significant effect [Wilks lambda = 
0.193, P < 0.001]. A post-hoc analysis indicated a significant (P < 0.001) difference in 
PPI deficits between the vehicle + vehicle group and vehicle + PCP (3.0 mg/kg) group 
at all dB groups (Figure 2). Pretreatment with SB (1000 mg/kg) significantly attenuated 
PCP-induced PPI deficits. However, L-701,324 (10 mg/kg) did not affect the effect of 
SB on PCP-induced PPI deficits (Figure 2). Furthermore, L-701,324 (10 mg/kg) did not 
affect PCP-induced PPI deficits in mice (Figure 2). 
A single administration of PCP (3.0 mg/kg, s.c.) markedly increased locomotion 
in mice. One-way ANOVA revealed significant differences among the four groups [F (3, 
35) = 6.17, P = 0.002]. Pretreatment with SB (1000 mg/kg) significantly (P < 0.01) 
attenuated PCP-induced hyperlocomotion in mice (Figure 2). In contrast, administration 
of SB (1000 mg/kg) alone did not affect spontaneous locomotion in mice.  
A single oral administration of SB (1000 mg/kg) did not alter plasma levels of 
D-serine, L-serine and glycine. In contrast, SB significantly decreased plasma levels of 
glutamine whereas SB significantly increased plasma levels of glutamate (Table 1). 
Furthermore, SB significantly increased the ratio of L-serine to glycine in plasma, 
 11 
suggesting that SB may affect L-serine – glycine cycle (Table 2). Moreover, SB 
significantly decreased the ratio of glutamine to glutamate in plasma, suggesting that SB 
may affect glutamine – glutamate cycle (Table 2).  
A single oral administration of SB (1000 mg/kg) did not alter tissue levels of 
D-serine and other amino acids except L-serine levels in striatum (Table 1). However, 
SB significantly increased the ratio of D-serine to L-serine in the striatum, but not 
frontal cortex and hippocampus. Furthermore, SB significantly decreased the ratio of 
glutamine to glutamate in the striatum, but not frontal cortex and hippocampus. These 
findings suggest that SB may affect D-serine – L-serine cycle and glutamine – 
glutamate cycle in the striatum (Table 2). 
Discussion  
In this study, we found that SB attenuated PPI deficits and hyperlocomotion in mice 
after administration of PCP. Furthermore, L-701,324 did not affect the effect of SB on 
PCP-induced PPI deficits, suggesting that activation at glycine-site of the NMDA 
receptor may not be involved in the mechanism of action of SB. This is the first report 
to demonstrate that SB is effective in the PCP model of schizophrenia. However, SB 
(1000 mg/kg) did not increase the tissue levels of D-serine in the mouse brain, 
indicating that D-serine in the brain may not be involved in the acute therapeutic action 
of SB in this model. In contrast, a single dose of SB significantly increased the ratio of 
D-serine to L-serine in the striatum, suggesting that SB may affect the D-serine – 
L-serine cycle. Therefore, it is likely that repeated administration of SB increases 
D-serine levels in the brain although a further study is needed to confirm this. 
Although DAAO inhibitors were proposed as a new therapeutic drug for 
schizophrenia, their clinical use has been largely unsuccessful [54, 55]. Ferraris et al. 
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[43] reported 5-chloro-benzo[d]isoxazol-3-ol (CBIO; IC50 = 1680 nM) as being a more 
potent DAAO inhibitor than SB (Ki ≈ 16 μM). In a subsequent report, we found that a 
single oral dose of CBIO (30 mg/kg) did not increase levels of D-serine in the plasma or 
frontal cortex, and that CBIO alone did not improve the NMDA receptor antagonist 
dizocilpine-induced PPI deficits in mice [48]. In addition, we found that a low dose of 
D-serine (30 mg/kg) did not improve dizocilpine-induced PPI deficits in mice, although 
this dose significantly increased plasma levels of D-serine [48]. Taken together, it is 
likely that the extensive inhibition of DAAO in the periphery and brain has a limited 
effect on brain or extracellular levels of D-serine, and that the behavioral effects of 
DAAO inhibitors may be very weak. In contrast, we found that co-administration of 
CBIO with D-serine (or D-alanine) increased brain levels of D-serine (or D-alanine) 
compared with D-serine (or D-alanine) alone, and that CBIO potentiated the effects of 
D-serine (or D-alanine) on dizocilpine-induced PPI deficits in mice [43, 48, 49]. 
Therefore, we proposed that combination therapy of D-serine (or D-alanine) with a 
DAAO inhibitor could reduce doses of D-serine (or D-alanine) in humans, particularly 
since the clinical doses of D-serine (or D-alanine) are quite high (30-60 mg/kg) [43, 48, 
49].  
DAAO shows very low activity in adult forebrains, with high activity in the adult 
cerebellum. Therefore, it is possible that this increase in cerebellar D-serine levels by 
DAAO inhibition, may in part confer antipsychotic effects, by augmenting 
D-serine-mediated regulation of NMDA receptors in the cerebellum [9, 56], although 
we did not measure these levels in the present study. Recent reports show that SB 
up-regulated brain-derived neurotrophic factor (BDNF) in mice [9, 57]. This implies 
that the therapeutic effect of SB may be mediated through increased BDNF levels, since 
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the TrkB agonist, 7,8-dihydroxyflavone attenuated the behavioral abnormalities of 
hyperlocomotion and PPI deficits in mice after administration of the stimulant 
methamphetamine [50, 58]. 
Glutamine – glutamate cycle in the glia – neuron communication is involved in 
the glutamatergic neurotransmission in the brain [6, 45, 46]. In this study, we found that 
SB significantly increased the ratio of glutamine to glutamate, a marker for glutamine – 
glutamate cycle, in plasma and striatum. These findings suggest that SB can affect 
glutamine – glutamate cycle in the striatum and plasma, resulting in the regulation of 
the NMDA receptor.  
Accumulating evidence suggests a role for inflammation and oxidative stress in 
the pathophysiology of schizophrenia [59-63]. SB is thought to have a potent 
anti-inflammatory effect via modulation of the mevalonate pathway and p21ras [64]. In 
addition, SB up-regulates the neuroprotective protein, DJ-1, a Parkinson disease protein, 
also via modulation of the mevalonate pathway [65]. Previously, we reported that potent 
anti-inflammatory and antioxidants, including minocycline and sulforaphane, attenuate 
behavioral abnormalities in mice after administration of PCP or methamphetamine [21, 
22, 47, 66, 67]. Taken together, it is possible that SB mediates its therapeutic action 
through anti-inflammatory and antioxidant pathways. Further detailed studies on 
molecular targets of SB are needed. 
Conclusions 
Our study suggests that SB shows potential antipsychotic activity in animal models of 
schizophrenia. It is possible that SB could be used for the effective and safe treatment of 
schizophrenia, particularly since SB is generally recognized as a safe food preservative. 
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In addition, the use of amino acids, including D-serine as biomarkers for treatment 
efficacy will be an interesting future development. 
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Figure legends 
Figure 1. Effect of SB on PCP-induced PPI deficits in mice  
One hour after a single oral administration of vehicle (10 ml/kg), or SB (100, 300 or 
1000 mg/kg), PCP (3 mg/kg) or saline (10 ml/kg) was administered s.c. to the mice. 
Each value is the mean ± S.E.M. (n = 17 - 21 per group). *P < 0.05, ***P < 0.001 as 
compared with the vehicle + PCP treated group. 
Figure 2. Effects of SB and L-701,324 on PCP-induced PPI deficits in mice  
Thirty minutes after a single oral administration of vehicle (10 ml/kg) or SB (1000 
mg/kg), L-701,304 (10 mg/kg) or vehicle (10 ml/kg) was administered i.p. to the mice. 
Thirty minutes after i.p. injection of L-701,304 (or vehicle), PCP (3 mg/kg) or saline (10 
ml/kg) was administered s.c. to the mice. Each value is the mean ± S.E.M. (n = 8 - 11 
per group). *P < 0.05, **P < 0.01, ***P < 0.001 as compared with the vehicle + PCP 
treated group. 
Figure 3. Effect of SB on PCP-induced hyperlocomotion in mice 
One hour after a single oral administration of vehicle (10 ml/kg) or SB (1000 mg/kg), 
PCP (3.0 mg/kg) or saline (10 ml/kg) was administered s.c. into the mice. Behavior 
(locomotion) in the mice was evaluated for 1 hour after administration of PCP. Each 
value is the mean ± S.E.M. (n = 8 - 12 per group). **P < 0.01, ***P < 0.001 as 
compared with the vehicle + PCP group  
 
 
 
 
5aline (10 ml/kg， s.c.) or 
PCP (3 mg/kg， s.c.) 
PPI test 
Vehicle (10 ml/kg， PO) or 
58 (100，300， 1000 mg/kg， PO) 
口Vehicle+ Saline 
??
??
?
???、 ?、』
?、???
???????， ， ? ? ?
? ? 、 ， ， ? ? ? ? ? ?
? ? 、
??
】
??
】
??
?
• Vehicle + PCP 
60 min 100 
90 
80 
70 
60 
50 
40 
30 
20 
10 
??
???
PP81 PP77 PP73 PP69 
。
5aline (10 ml/kg， s.c.) or 
PCP (3 mg/kg， s.c.) 
PPI test 
Vehicle (10 ml/kg， i.p.) or 
L・701，304(10 mg/kg， i.p.) 
Vehicle (10 ml/kg， PO) or 
58 (1000 mg/kg， PO) 
30 min 30 min 100 
*** 
*** 
90 
口Vehicle+ Vehicle + Saline 
ロSB+ L-701.324 + PCP 
.Vehicle + L-701 ，324 + PCP 
• Vehicle + Vehicle + PCP 
口SB+ Vehicle + PCP 
*** 
* * 
*** 
80 
70 
60 
50 
40 
30 
20 
10 
??
???
PP81 PP77 PP73 PP69 
。
-旬、
ω 
40 4 
コz -ーE 
o 
u) 、-
4ω d 
z 
コ。
υ 
← 噌帽0 4 
Vehicle (10 ml/kg， PO) or 
58 (1000 mg/kg， PO) 
60 min 
20000 
15000 
10000 
5000 
。
Vehicle + 5aline 
*** 
58 + 5aline 
5aline (10 ml/kg， s.c.) or 
PCP (3 mg/kg， s.c.) 
Locomotion 
60 min 
* 
Vehicle + PCP 58 + PCP 
s・
